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Corticosteroids on b2-Adrenoceptors in Acute Asthma
To the Editor:
We read with interest the findings of Moran and colleagues showing
equally rapid reductions in blood eosinophils with oral prednisolone
and subcutaneous benralizumab (1) in patients with poorly
controlled asthma. The authors go on to suggest that benralizuamb
might be used as an alternative to corticosteroids for the treatment
of acute exacerbations of eosinophilic asthma. Their data was not
obtained in the setting of acute severe airflow obstruction, where
airway smooth muscle constriction also plays a key role in airflow
limitation in addition to endobronchial inflammation. Pointedly,
they did not comment on whether the acute fall in eosinophils was
accompanied by a commensurate improvement in airway geometry
as FEV1. In this regard, the findings of Moran and colleagues do
not take into account the acute facilitatory effect of systemic
corticosteroids such as prednisolone on airway smooth muscle
in terms of rapid upregulation and resensitization of b2-
adrenoceptors in patients with acute asthma, especially those who
have been taking inhaled corticosteroids with long-acting b2-
agonists (2). Moreover, benralizumab exhibits antiinflammatory
activity by suppressing eosinophils alone, whereas corticosteroids
have more broad-spectrum activity on a variety of inflammatory
cells in asthma. Notably, benralizumab is also considerably
more expensive than oral prednisolone. Hence, although we
would advocate for benralizumab as a suitable long-term treatment
for reducing exacerbations in severe eosinophilic asthma, we
would not endorse its routine use for treatment in acute asthma. n
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Reply to Lipworth et al.
From the Authors:
We thank Dr. Lipworth and colleagues for their interest in
our work published recently in the Journal (1). They rightly point
out that the biology of asthma attacks is more complex than
blood eosinophils alone and that corticosteroids have a wide
range of other potentially relevant antiinflammatory effects.
However, local treatment with inhaled corticosteroids (ICS) is
usually the mainstay of patients with frequent eosinophilic
exacerbations, and therefore in the great majority of patients,
the key question is what oral corticosteroids (OCS) add to
ICS in an acute attack (2) and whether this effect is seen
with benralizumab. We suggest that depletion of circulating
eosinophils is the only effect OCS are likely to have that are not
shared with ICS (3).
Because OCS are known to have severe side effects, and in
noneosinophilic exacerbations of chronic obstructive pulmonary
disease they are actually harmful (4), it would be a significant
advance to determine whether a combination of ICS and rapidly
acting anti–IL-5 treatment would cover all the benefits of OCS in
acute asthma while mitigating the harms of OCS. With respect to
this, we recently published a case report (5) that showed the
addition of benralizumab to ICS resulted in a dramatic
improvement of peak flow and FEV1 within 6 hours when given
to treat an asthma attack in a patient in whom systemic
corticosteroids were contraindicated. We believe that these
findings support the idea that systemic targets of benralizumab
that express the IL-5 receptor (such as eosinophils and basophils)
play a pivotal role in sustaining the nonbronchodilator responsive
airflow limitation seen in asthma attacks.
The use of benralizumab in acute asthma may also
provide other benefits. Treatment failure is a major issue in
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